Preemptive endoluminal vacuum therapy to reduce anastomotic leakage after esophagectomy: a game-changing approach? by Gubler, C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Preemptive endoluminal vacuum therapy to reduce anastomotic leakage
after esophagectomy: a game-changing approach?
Gubler, C; Vetter, D; Schmidt, H M; Müller, P C; Morell, B; Raptis, D; Gutschow, C A
Abstract: Endoluminal vacuum therapy (EVT) is an accepted treatment for anastomotic leakage (AL)
after esophagectomy. A novel concept is to use this technology in a preemptive setting, with the aim
to reduce the AL rate and postoperative morbidity. Preemptive EVT (pEVT) was performed intra-
operatively in 19 consecutive patients undergoing minimally invasive esophagectomy, immediately after
completion of esophagogastrostomy. Twelve patients (63%) were high-risk cases with severe comorbidity.
The EVT device was removed routinely three to six (median 5) days after esophagectomy. The endpoints
of this study were AL rate and postoperative morbidity. There were 20 anastomoses at risk in 19 patients.
One patient (5.3%) experienced major morbidity (Clavien-Dindo grade IIIb) unrelated to anastomotic
healing. He underwent open reanastomosis at postoperative day 12 with pEVT for redundancy of the
gastric tube and failure of transition to oral diet. Mortality after 30 days was 0% and anastomotic heal-
ing was uneventful in 19/20 anastomoses (95%). One minor contained AL healed after a second course
of EVT. Except early proximal dislodgement in one patient, there were no adverse events attributable
to pEVT. The median comprehensive complication index 30 days after surgery was 20.9 (IQR 0-26.2).
PEVT appears to be a safe procedure that may have the potential to improve surgical outcome in patients
undergoing esophagectomy.
DOI: https://doi.org/10.1093/dote/doy126
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-160962
Journal Article
Published Version
Originally published at:
Gubler, C; Vetter, D; Schmidt, H M; Müller, P C; Morell, B; Raptis, D; Gutschow, C A (2019). Preemp-
tive endoluminal vacuum therapy to reduce anastomotic leakage after esophagectomy: a game-changing
approach? Diseases of the Esophagus, 32(7):Epub ahead of print.
DOI: https://doi.org/10.1093/dote/doy126
Diseases of the Esophagus (2018) 0, 1–6
DOI: 10.1093/dote/doy126
Original Article
Preemptive endoluminal vacuum therapy to reduce anastomotic leakage
after esophagectomy: a game-changing approach?
C. Gubler,1 D. Vetter,2 H. M. Schmidt,2 P. C. Mu¨ller,2 B. Morell,1 D. Raptis,3 C. A. Gutschow2
1
Department of Gastroenterology, and,
2
Department of Visceral and Transplant Surgery, University Hospital
Zurich, Zurich, Switzerland, and
3
Department of HPB Surgery and Liver Transplantation, Royal Free London
NHS Foundation Trust, London, United Kingdom
SUMMARY. Endoluminal vacuum therapy (EVT) is an accepted treatment for anastomotic leakage (AL) after
esophagectomy. A novel concept is to use this technology in a preemptive setting, with the aim to reduce the
AL rate and postoperative morbidity. Preemptive EVT (pEVT) was performed intraoperatively in 19 consecu-
tive patients undergoing minimally invasive esophagectomy, immediately after completion of esophagogastrostomy.
Twelve patients (63%) were high-risk cases with severe comorbidity. The EVT device was removed routinely three
to six (median 5) days after esophagectomy. The endpoints of this study were AL rate and postoperative morbidity.
There were 20 anastomoses at risk in 19 patients. One patient (5.3%) experienced major morbidity (Clavien–Dindo
grade IIIb) unrelated to anastomotic healing. He underwent open reanastomosis at postoperative day 12 with pEVT
for redundancy of the gastric tube and failure of transition to oral diet. Mortality after 30 days was 0% and anas-
tomotic healing was uneventful in 19/20 anastomoses (95%). One minor contained AL healed after a second course
of EVT. Except early proximal dislodgement in one patient, there were no adverse events attributable to pEVT. The
median comprehensive complication index 30 days after surgery was 20.9 (IQR 0–26.2). PEVT appears to be a safe
procedure that may have the potential to improve surgical outcome in patients undergoing esophagectomy.
KEYWORDS: anastomotic leakage, complications, minimally invasive esophagectomy, outcome research.
INTRODUCTION
Anastomotic leakage (AL) is a frequent and life-
threatening complication after esophagectomy.1,2
Patients with severe comorbidities are at increased
risk.3-5 The pathophysiology of AL is likely to be
multifactorial and involves technical issues, local
Address correspondence to: Prof. Christian A. Gutschow, Division
Head Upper Gastrointestinal Surgery, Department for Surgery
and Transplantation, University Hospital Zurich, Ra¨mistrasse,
1008091 Zurich, Switzerland. Email: christian.gutschow@usz.ch
Christoph Gubler and Diana Vetter contributed equally to this
work.
Specific author contributions: Study design, performing the
experiments, drafting the manuscript: Christoph Gubler; Study
design, performing the experiments, drafting the manuscript:
Diana Vetter; Performing the experiments, interpretation of data,
critical revision of the manuscript: Henner M. Schmidt, Philip C.
Mu¨ller, Bernhard Morell; Statistical analysis, interpretation of
data, critical revision of the manuscript: Dimitri Raptis; Study
design, performing the experiments, interpretation of data,
drafting the manuscript: Christian A. Gutschow. All authors gave
their final approval.
Financial support: The study was funded by institutional means.
Conflicts of interest: The authors declare that they have no conflict
of interest.
ischemia, bacterial superinfection, and inflamma-
tion.6,7
Therapeutic strategies for AL have evolved dramat-
ically over the last years and interventional endoscopy
has replaced surgical revision in most situations. In
this context, endoluminal vacuum therapy (EVT) has
become an important therapeutic tool. The ways
in which EVT works involve continuous removal
of secretions, improvement of interstitial edema and
microcirculation, and induction of granulation. A
number of retrospective studies have established proof
of the EVT concept with excellent outcome and low
complication rates.8,9
A novel idea is to use the EVT technology in a
preemptive setting with the aim of preventing AL
and reducing postoperative morbidity. In a recent
case series, early EVT in patients without leak but
with endoscopically proven anastomotic ischemia was
effective in six of eight patients.10 Likewise, in a live
porcine model, intraoperative application of EVT in
esophagogastric anastomoses with intentional 1 cm
defects resulted in complete healing.11 With this in
C© The Author(s) 2018. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights
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mind and considering the high incidence and delete-
rious effects of AL, we implemented preemptive EVT
(pEVT) in patients undergoing esophagectomy and
gastric tube reconstruction.
PATIENTS ANDMETHODS
From a prospectively maintained database, we
identified 19 consecutive patients who underwent
esophagectomy with intraoperative pEVD between
November 2017 and May 2018 in our department. In
our institution, we perform 25–30 esophagectomies
per year with an AL rate of 8% over the last 50 cases
before implementation of pEVT. Institutional review
board approval was obtained (2018–01198).
Records of patients were reviewed with respect to
demographic characteristics, oncological parameters,
surgical procedures, and the postoperative course up
to 90 days after surgery. The endpoints of this study
were postoperative morbidity and AL rate, defined
according to the Esophageal Complications Con-
sensus Group (ECCG) (Table 1),12 the Clavien–Dindo
(CD) classification, and the comprehensive complica-
tion index (CCI).
Surgical technique and perioperative management
The surgical procedures were total (laparo-
scopic/thoracoscopic) minimally invasive Ivor Lewis
esophagectomy (ttMIE) with high intrathoracic
circular stapled end-to-side esophagogastrostomy
(n = 18) and minimally invasive retrosternal gastric
tube reconstruction with circular stapled end-to-side
cervical esophagogastrostomy in a patient under-
going secondary reconstruction after esophagectomy
(n = 1). In all cases, we created a double-stapled
25 mm circular anastomosis using the OrVil device
(Medtronic, Minneapolis, USA). In addition, an
omental wrap was placed routinely between the
trachea and anastomosis. At the end of the procedure,
two chest tubes (20 French) were inserted in the
right hemithorax, one close to the anastomosis at
the apex and one posterior-basal. Another basal
thoracic drain was placed in the left chest. Feeding
jejunostomies were inserted in high-risk situations or
in patients with preoperative weight loss >10% only.
Enteral nutrition was started over the jejunostomy
on postoperative day 1 and advanced as tolerated,
while a liquid oral diet was started after removal of
the Eso-SPONGE. Antibiotic prophylaxis (Tazobac,
Pfizer PFE GmbH, Zurich, Switzerland) was given
routinely for 5–7 days.
Endoluminal vacuum therapy
Immediately after completion of the anastomosis, the
Eso-SPONGE (an open-pored polyurethane sponge
Table 1 Patient characteristics (n = 19)
Age, years (median, IQR) 66 (62–71)
BMI, kg/m2 (median, IQR) 27.1 (24.6–30.6)
Male, n (%) 18 (95)
WHO/ECOG performance status, n (%)
Grade 0 7 (37)
Grade I 10 (53)
Grade II 2 (11)
ASA status, n (%)
Grade I–II 8 (31)
Grade III 10 (61)
Grade IV 1 (8)
Charlson comorbidity index (median, IQR) 3 (2–5)
Histology, n (%)
AC 15 (79)
SCC 3 (16)
Benign 1 (5)
Tumor location, n (%)∗
Proximal half of esophagus 3 (16)
Distal half of esophagus 11 (58)
Esophagogastric junction (Siewert II) 4 (21)
Preoperative therapy, n (%)∗
None 6 (50)
Radiochemotherapy 11 (58)
Chemotherapy 1 (5)
Surgical approach
Laparoscopic/thoracoscopic Ivor Lewis 18 (92)
Retrosternal gastric tube reconstruction 1 (8)
Reanastomosis for redundant gastric tube 1 (8)
UICC stages, n (%)∗
I 5 (27.8)
Ia 1(5.6)
Ib 2(11.1)
II 3 (16.7)
IIIA 3 (16.7)
IIIB 3 (16.7)
Iva 1 (5.6)
∗Patients with malignant indication n = 18.
IQR, interquartile range; BMI, body mass index; ECOG, Eastern
Cooperative Oncology Group; ASA, American Society of Anesthe-
siologists; AC, adenocarcinoma; SCC, squamous cell carcinoma;
UICC, Union Internationale Contre le Cancer TNMClassification
for Esophageal Cancer 8th edition.
fitted to a gastric tube, B. BraunMelsungen AG,Mel-
sungen, Germany) was placed endoscopically via an
overtube. The central part of the sponge was posi-
tioned exactly at the level of the anastomosis. The
tube was routed transnasally and then connected to a
vacuum pump (Medela Thopaz, Medela Healthcare,
Baar, Switzerland), generating a continuous negative
pressure of 75 mmHg. The tube was marked and tape-
fixed at the nostril to monitor and prevent disloca-
tion. Throughout therapy, the Eso-SPONGE system
was checked 6-hourly for leakage and dislocation. The
sponge was removed after 4 to 6 days via gastroscopy.
The timing of the endoscopic sponge extraction varied
due to the limited availability of our endoscopy service
for routine procedures on weekends. After removal,
the anastomosis and the gastric tube were assessed
endoscopically to exclude leakage or ischemia, and the
pylorus was evaluated for spasm. Repeat endoscopy,
contrast radiography, or computed tomography to
exclude late AL was performed according to the fur-
ther clinical course.
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Table 2 Anastomotic leak defined according to the Esophageal
Complications Consensus Group12
Definition: Full-thickness gastrointestinal defect involving esoph-
agus, anastomosis, staple line, or conduit irrespective of presentation
or method of identification
Type I Local defect requiring no change in therapy or
treated medically or with dietary modification
Type II Localized defect requiring interventional but not
surgical therapy, for example, interventional
radiology drain, stent or bedside opening, and
packing of incision
Type III Localized defect requiring surgical therapy
Fig. 1 Uneventful healing of the esophagogastrostomy with gran-
ulation tissue (arrows) after 5 days of preemptive endoluminal
vacuum therapy.
Statistical analysis
Patient characteristics are expressed as mean (stan-
dard deviation) or median (IQR) for continuous vari-
ables and frequencies and percentages for categorical
variables, respectively.
RESULTS
There were 20 anastomoses at risk in 19 consecu-
tive and unselected patients undergoing MIE between
November 2017 and May 2018. One of the ttMIE-
patients of this series underwent rethoracotomy and
high intrathoracic reanastomosis with pEVT at post-
operative day 12 for gastric tube redundancy pre-
venting adequate oral feeding. Patient characteristics
are shown in Table 2.
Technical aspects of pEVT
In one patient, proximal dislocation of the device
occurred at postoperative day 1. He underwent imme-
diate endoscopic repositioning of the sponge without
any further complications. There were no other
adverse events related to pEVT. In particular, there
were no bleeding episodes, tracheobronchial fistulae,
air leaks, or disconnections. In all patients, endoscopic
removal of the Eso-SPONGE system was performed
routinely 5 (IQR 3–6) days after surgery without com-
plications. Technical-procedural aspects of sponge
extraction and anastomotic healing did not differ sig-
nificantly in patients undergoing early or later removal
of the device.
Anastomotic healing
Uneventful primary healing occurred in 19 of 20
anastomoses (Fig. 1) (AL rate 5%, stenosis rate
0%). In one patient after ttMIE, a 2 mm contained
AL (ECCG type 2) was detected during endoscopic
sponge removal (Fig. 2a). This patient was an amer-
ican society of anesthesiologists grade III high-risk
case with a Charlson comorbidity index of 7 (insulin-
dependent diabetes type II, history of myocardial
infarction and chronic kidney disease). Throughout
the postoperative course, he remained asymptomatic
without clinical signs of infection with unremarkable
c-reactive protein levels and leukocyte counts. After a
second course of EVT over 5 days, the leak was closed
(Fig. 2b) and followed by an uneventful clinical course
until discharge 20 days after surgery.
Postoperative morbidity (Table 3)
Postoperative intensive care unit and hospital stay
was 1 (IQR 1–3) and 13 (IQR 11–18) days, respec-
tively. There were no deaths in this series and none of
the patients experienced morbidity > CD IIIb. Seven
patients (37%) had no postoperative complication,
eight patients (42%) developed one complication, and
four patients (21%) experienced two or more com-
plications. The highest morbidity seen in this series
was a CD IIIb complication in a patient undergoing
revisional surgery at postoperative day 12 for redun-
dancy of the gastric tube with failure of transition to
oral diet. Open transthoracic revisional surgery was
performed with shortening of the interponate, end-
to-side reanastomosis, and pEVD. The anastomotic
healing of both the primary and revisional anasto-
mosis was uneventful.
Four patients (21%) had a CD IIIa complication.
In detail, one patient developed an ECCG type 2 AL
that was managed conservatively (EVT), two patients
showed a pleural effusion that was treated with tho-
racic drainage, and one patient had a pyloric outlet
obstruction requiring a single endoscopic dilation.
The median CCI 30 days after surgery was 20.9 (IQR
0–26.2).
DISCUSSION
This is the first clinical series to evaluate the effect
of intraoperative pEVT on anastomotic healing and
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Fig. 2 (A) 2 mm anastomotic leak (arrow) at initial diagnosis on postoperative day 5. (B) The leak (arrow) was sealed and contained after
a second stage of endoluminal vacuum therapy over 5 days.
morbidity after esophagectomy. In contrast to other
research,10 the Eso-SPONGE device was placed
during surgery, immediately after completion of the
anastomosis. The clinical outcome in our study cohort
was promising with zero 30-day mortality (5.6% at
90 days) and a single ECCG grade 2 AL (AL rate
5%). Compared with 50 consecutive patients under-
going esophagectomy in our institution before imple-
mentation of pEVT, the AL rate in the present series
was lower (5% vs 8%) and the clinical course of anas-
tomotic failure was remarkably benign without septic
complications.
Themechanism of action of EVT involves increased
anastomotic blood flow, modulation of cytokines
and chemoreceptor-mediated cell signaling, leading to
enhanced angiogenesis and deposition of granulation
tissue.13 In the preemptive setting after esophagec-
tomy (pEVT), this mechanism may help to seal minor
unrecognized anastomotic defects at a very early
stage, thus preventing contamination of the medi-
astinum and the pleural space.
In AL after esophagectomy, endoscopic negative
pressure therapy has the potential to convert ‘free’
into ‘contained’ AL by creating a closed, granulating,
and well-drained extraluminal cavity. A contained
anastomotic defect is sealed by the surrounding
healthy tissue and conservative treatment is successful
in 80–100%.9 To achieve this, the Eso-SPONGE may
be positioned intra- or extraluminally, depending on
the size of the abscess cavity.14,15 In our experience,
extraluminal (intracavitary) sponge positioning is
mainly indicated in larger paraanastomotic caverns
with a relevant defect of the suture line. Extraluminal
placement may also be combined with a partially
covered self-expandable metal stent (stent-over-
sponge technique).9 However, one should keep in
mind that positioning of the sponge outside the
esophagogastric lumen carries the risk of severe
hemorrhage from intrathoracic vessels.16 Therefore,
the benefits of extraluminal Eso-SPONGE place-
ment must be carefully counterbalanced against its
potential risks.
The evidence published on pEVT in esophageal
surgery is extremely limited. In a pilot study on
domestic pigs undergoing Ivor Lewis esophagectomy,
11 intentional anastomotic defects were treated with
EVT (n = 4) or received no specific treatment (con-
trol group, n= 6). Three controls died within 24 hours
and were excluded from analysis, whereas three con-
trols surviving more than 24 h showed frank AL and
pleural contamination with gastric contents. In con-
trast, no leaks were detected in the EVT group after
a follow-up of 3–7 days (p = 0.03) and the authors
concluded that EVT may have the potential to close
leaks that otherwise would not heal without surgical
or endoscopic intervention.
A retrospective case-series investigated early post-
operative EVT 10 in patients undergoing Ivor Lewis
esophagectomy with endoscopically proven anas-
tomotic ischemia. EVT led to complete mucosal
recovery without AL in six of eight patients. Two
patients developed small, contained ALs that were
successfully treated by subsequent courses of EVT.No
EVT-related adverse events were noted. The authors
concluded that EVT may play an important role
in the treatment of anastomotic ischemia following
esophagectomy.
Both studies cited above focus on treatment of
ischemia or AL, which represents a well-established
indication for EVT. In contrast, the idea of our study
was to promote primary anastomotic healing in a
technically sound surgical situation that carries a high
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Table 3 Postoperative outcomes (20 anastomoses at risk in 19
patients)
Complications, n (%)
Any type 12 (63)
Minor (CD II–IIIa) 7 (58)
Major (CD IIIb–V) 1 (5)
Anastomotic leak∗ 1 (5)
Conduit necrosis 0 (0)
Chyle leak 0 (0)
Gastrointestinal event 4 (21)
Pulmonary event 5 (26)
Cardiac event 5 (26)
Thromboembolic event 0 (0)
Urologic event 0 (0)
Infection 3 (16)
Neurologic event 3 (16)
Wound infection 0 (0)
Blood product utilization, n (%)
Intraoperative 0 (0)
Postoperative 1 (5)
Intra- and postoperative 1 (5)
ICU stay, median (IQR) 1 (1–3)
Hospital stay, median (IQR) 13 (11–18)
Readmission rate within 90 days of discharge, n (%)
Related to esophagectomy 3 (16)
Unrelated to esophagectomy 0 (0)
CCI at 30 day after discharge, median (IQR) 20.9 (0–26.2)
Mortality, n (%)
30-day 0 (0)
90-day 1 (5.6)
∗Twenty anastomoses at risk in 19 patients.
IQR interquartile range; CD, Clavien–Dindo classification;
ICU, intensive care unit; CCI, comprehensive complication
index.
intrinsic risk for perioperative morbidity. Thus, to our
best knowledge, this is the first clinical series investi-
gating a truly preemptive use of EVT after esophagec-
tomy in humans.
Undeniably, our study has some limitations. First,
an additional endoscopic procedure to remove the
Eso-SPONGE was required in all patients, and the
risk of endoscopy-associated complications must be
carefully weighed against the potential benefits of
pEVT. Furthermore, there are no accepted standards
for ideal treatment duration and optimal negative
system pressure. Therefore, those parameters had to
be chosen empirically from our experience with EVT
for anastomotic fistula. However, complete removal
of the sponge without residua was unproblematic and
the negative pressure of 75 mmHg was sufficient to
promote visible formation of granulation tissue.
Proximal dislocation of the device occurred in one
patient at postoperative day one. Dislodgement of
nasogastric tubes is a well-known problem occur-
ring in up to 62% of patients during the early post-
operative phase.17 In patients at risk, we switched
from traditional nasal tape fixation to a specifically
designed anchoring device (AMT Bridle, Applied
Medical Technology, Brecksville, OH) with no further
dislodgements seen in this series. Another concernwas
that intraluminal placement of the sponge could pro-
mote aspiration of saliva. On the other hand, occlu-
sion of the anastomotic area may also have a pro-
tective effect for aspiration pneumonia, because the
contents of the gastric tube are completely sealed off
the supraglottic area. Either way, no signs of aspira-
tion pneumonia were detected in our series. Also, we
are not able to report long-term endoscopic follow-
up in our patients. Thus, late complications of pEVT
like anastomotic strictures may have been missed
and should be evaluated in future prospective clinical
trials.18 However, most patients treated in this series
had uneventful transition to a normal diet.
In conclusion, preemptive endoluminal vacuum
therapy is a safe procedure that may reduce AL
formation and related morbidity by promoting pri-
mary anastomotic healing. Furthermore, pEVT is
likely to seal potential minor full-thickness defects at
a very early stage and thereby prevent free leakage
in patients undergoing esophagectomy. Preemptive
endoluminal vacuum therapy may be particularly
valuable in patients with relevant comorbidities and
increased risk for AL. Identification of subpopula-
tions that will benefit most from pEVT should be the
next step of clinical research in this field.
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